fluoxetine has been researched along with olanzapine in 153 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.96) | 18.2507 |
| 2000's | 97 (63.40) | 29.6817 |
| 2010's | 45 (29.41) | 24.3611 |
| 2020's | 8 (5.23) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Jia, L; Sun, H | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Epperson, CN; McDougle, CJ; Potenza, MN; Wasylink, S | 1 |
| Epperson, CN; Longhurst, JG; McDougle, CJ; Potenza, MN; Wasylink, S | 1 |
| de la Sablonnière, JF; Mottard, JP | 1 |
| Heal, DJ; Kilpatrick, IC; Needham, PL; Rowley, HL | 1 |
| Elliott, MA; Koran, LM; Ringold, AL | 1 |
| Bao, J; Bymaster, FP; Perry, KW; Potts, BD; Tollefson, GD; Wong, DT; Zhang, W | 1 |
| Nelson, LA; Swartz, CM | 1 |
| Buras, WR; Bymaster, FP; Feldman, PD; Gannon, KS; Jacobs, TG; Meltzer, HY; Shelton, RC; Spencer, KA; Stahl, S; Tohen, M; Tollefson, GD; Zhang, W | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Farmer, A; Marusic, A | 1 |
| Hallett, J; Harel, Z; Kiessling, L; Riggs, S; Vaz, R | 1 |
| Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF | 1 |
| Aldurra, G; Crayton, JW | 1 |
| Ashton, AK | 1 |
| Benazzi, F | 1 |
| Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A | 1 |
| de Suray, JM; Gangji, D; Gossen, D; Onkelinx, C; Vandenhende, F | 1 |
| Kline, NA; Matloff, JL; Stein, MB | 1 |
| Bottonari, KA; Dording, CM; Fava, M; Irvin, R; Matthews, JD; Mischoulon, D; Polania, LM | 1 |
| Safranko, I | 1 |
| Schatzberg, AF | 1 |
| Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L | 1 |
| Bowden, CL | 2 |
| Shelton, RC | 2 |
| Detweiler, MB; Trinkle, DB | 1 |
| Gronier, BS; Rasmussen, K | 1 |
| Goyal, A; Hallas, BH; Horowitz, AT; Horowitz, JM; Ramdeen, N; Torres, G | 1 |
| Birnbaum, H; Corey-Lisle, PK; Dube, S; Greenberg, P; Marynchenko, M | 1 |
| Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E | 1 |
| Andersen, SW; Corya, SA; Detke, HC; Dubé, S; Kelly, LS; Sanger, TM; Van Campen, LE; Williamson, DJ | 1 |
| Bymaster, FP; Koch, S; Perry, KW | 1 |
| Drobizhev, MIu; Kozyrev, VN; Kraeva, GK; Kubrakov, MA; Smulevich, AB | 1 |
| Baker, RW; Namjoshi, MA; Risser, R; Shi, L; Swindle, R; Tohen, M; Yu, X | 1 |
| Blier, P; Goodman, WK; Mandoki, M; Murphy, TK; Shapira, NA; Ward, HE; Yang, MC | 1 |
| Fumagalli, F; Gennarelli, M; Maragnoli, ME; Racagni, G; Riva, MA | 1 |
| Barth, VN; Huff, KD; Phebus, LA; Rasmussen, K; Seager, MA | 1 |
| Chopra, P; Ng, C; Schweitzer, I | 1 |
| Ordway, GA; Szebeni, K | 1 |
| Andersen, SW; Rothschild, AJ; Sanger, TM; Schatzberg, A; Tohen, MF; Tollefson, GD; Van Campen, LE; Williamson, DJ | 1 |
| Frankenburg, FR; Parachini, EA; Zanarini, MC | 1 |
| Gillman, PK | 1 |
| Duman, RS; Fujioka, T; Kodama, M | 1 |
| Baldessarini, RJ; Calabrese, JR; Colom, F; Hennen, J; Martínez-Arán, A; Sánchez-Moreno, J; Tohen, M; Vieta, E; Yatham, LN | 1 |
| Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G | 1 |
| Christensen, RC | 1 |
| Barth, VN; Phebus, LA; Rasmussen, K; Seager, MA | 1 |
| Phillips, KA | 1 |
| Altshuler, LL; Briggs, SD; Case, M; Corya, SA; Keck, PE; Ketter, TA; McElroy, SL; Tohen, M | 1 |
| Menaster, M | 1 |
| Amsterdam, JD; Shults, J | 1 |
| Adell, A; Amargós-Bosch, M; Artigas, F | 1 |
| Calabrese, JR; Elhaj, O; Gajwani, P; Gao, K | 1 |
| Howell, LL; Kimmel, HL; Lindsey, KP; Wilcox, KM | 1 |
| Hoge, EA; Kinrys, G; Mick, E; Oppenheimer, J; Pollack, MH; Simon, NM; Worthington, JJ; Zalta, AK | 1 |
| Adetunji, BA; Williams, AB | 1 |
| Briggs, SD; Case, M; Corya, SA; Sanger, TM; Shelton, RC; Tollefson, GD; Van Campen, LE; Williamson, DJ | 1 |
| Andersen, SW; Clemow, DB; Corya, SA | 1 |
| Stephenson, GA | 1 |
| Ahl, J; Baker, RW; Brown, E; Perlis, RH; Tohen, M; Williamson, D | 1 |
| Owen, RT | 1 |
| Dufel, S; Paige, T; Vena, J | 1 |
| Briggs, SD; Case, M; Corya, SA; Sanger, TM; Tollefson, G; Williamson, D | 1 |
| Case, MG; Corya, SA; Keck, PE; Lin, DY; Perlis, RH; Tohen, MF; Williamson, DJ | 1 |
| Adams, DH; Brown, EB; Deldar, A; Keck, PE; McElroy, SL; Tohen, M; Williamson, DJ | 1 |
| Koht, J; Refsum, H; Solberg, DK | 1 |
| Fountoulakis, KN; Iacovides, A; Kaprinis, GS; Koumaris, V; Siamouli, M | 1 |
| Bradford, DW; Butterfield, MI; Grobin, AC; Khisti, RT; Lieberman, JA; Madison, RD; Marx, CE; Massing, MW; Morrow, AL; Shampine, LJ; Trost, WT | 1 |
| Moreira-Almeida, A; Pietrobon, R | 1 |
| Cai, NS; Fan, WH; Ge, JB; He, B; Hu, DY; Huang, Y; Jin, HG; Lu, GP; Ni, YF; Qi, WH; Sun, BG; Wei, M; Wu, SY; Wu, ZG; Zhang, FR; Zheng, AL | 1 |
| Case, M; Corya, SA; Dubé, S; Henley, DB; Osuntokun, O; Sanger, TM; Thase, ME; Watson, SB | 1 |
| Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G | 1 |
| Berk, M; Calabrese, JR; Malhi, GS; Mitchell, PB; Ng, F; Tohen, M; Wang, WV | 1 |
| Briggs, SD; Case, M; Dubé, S; Thase, ME; Tohen, M; Tollefson, GD; Van Campen, LE | 1 |
| Bánki, CM | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Salo, R; Wolf, J | 1 |
| Berk, M; Dodd, S | 1 |
| Adams, DH; Brown, E; Degenhardt, E; Dunner, DL; Houston, JP; Keck, PE; McElroy, SL; Tohen, M | 1 |
| Nierenberg, AA | 1 |
| Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB | 1 |
| Baldessarini, RJ; Berk, M; Colom, F; Tohen, M; Vieta, E; Wang, W | 1 |
| Jaramillo, MT; Molina-Hernández, M; Olivera-Lopez, JI; Téllez-Alcántara, NP | 1 |
| Cruz, N; Goikolea, JM; Sanchez-Moreno, J; Torres, F; Valentí, M; Vieta, E | 1 |
| Bobo, WV; Shelton, RC | 2 |
| Fajutrao, L; Liu, S; Locklear, J; Paulsson, B | 1 |
| Colom, F; Girardi, P; Kotzalidis, GD; Mazzarini, L; Pacchiarotti, I; Sanchez-Moreno, J; Vieta, E | 1 |
| Agostinho, FR; Castro, AA; Ferreira, GK; Jeremias, IC; Quevedo, J; Réus, GZ; Rezin, GT; Scaini, G; Streck, EL; Zugno, AI | 1 |
| Pathak, A; Rajput, SJ | 1 |
| Barraco, A; Benazzi, F; Berk, M; Frye, MA; Tohen, M; Wang, W | 1 |
| Adams, DH; Breier, A; Farmen, M; Fijal, B; Houston, JP; Perlis, RH; Sutton, VK | 1 |
| Croxtall, JD; Scott, LJ | 1 |
| Burke, SJ; Case, M; Durell, TM; Thase, ME; Tohen, M; Trivedi, MH | 1 |
| Kenchaiah, BK; Kumar, S; Tharyan, P | 1 |
| Aström, M; Chatterton, ML; Ekman, M; Günther, O; Locklear, J; Miltenburger, C; Paulsson, B; Vieta, E | 1 |
| Agostinho, FR; Benedet, J; Ferraro, AK; Quevedo, J; Réus, GZ; Ribeiro, KF; Rochi, N; Scaini, G; Streck, EL; Stringari, RB | 1 |
| Brecher, M; Calabrese, JR; Carlson, BX; Edwards, S; Eudicone, JM; Evoniuk, G; Ganocy, SJ; Jansen, W; Kemp, DE; Leon, AC; Minkwitz, M; Pikalov, A; Stassen, HH; Szegedi, A; Tohen, M; Van Willigenburg, AP | 1 |
| Bishop, JR; Dharia, S; Ellingrod, VL; Fijal, B; Hoffmann, VP; Houston, J; Jacobson, JG | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Frye, MA | 1 |
| Boutelle, K; Cromley, T; Duvvuri, V; Kaye, WH; Klabunde, M | 1 |
| Agostinho, FR; Kapczinski, F; Panizzutti, BS; Pfaffenseller, B; Quevedo, J; Réus, GZ; Ribeiro, KF; Stertz, L; Stringari, RB | 1 |
| Işik, U; Korkmaz, H; Korkmaz, S | 1 |
| Borovinskaya, M; Plakogiannis, FM; Robert, B | 1 |
| Alexander, S; Danabal, P; Gopinath, S; Kumar, RS | 1 |
| Rogóż, Z; Skuza, G | 1 |
| Dugad, P; Dulawa, SC; Klenotich, SJ; Le Grange, D; McMurray, MS; Roitman, JD; Seiglie, MP | 1 |
| Aris, V; Fijal, BA; Heinloth, AN; Houston, JP; Lau, K; Liu, W; Perlis, RH | 1 |
| Agarwal, M; Ghormode, D; Grover, S; Hegde, A; Malhotra, N; Somaiya, M | 1 |
| Akar, F; Celikyurt, IK; Erden, F; Gumuslu, E; Kır, HM; Kokturk, S; Mutlu, O; Ulak, G | 1 |
| Raghunath, A | 1 |
| D'iakonov, AL; Lobanova, IV | 1 |
| Dubovsky, SL | 1 |
| Akar, F; Celikyurt, IK; Cine, N; Gumuslu, E; Mutlu, O; Sunnetci, D; Ulak, G | 1 |
| Ketter, TA | 1 |
| Cornelius, V; Smith, L; Taylor, DM; Young, AH | 1 |
| EL-Kimary, EI; Ragab, MA | 1 |
| Aragones, JM; Blanch, CE; Escote-Llobet, S; Guillen-Font, A | 1 |
| Asaoka, N; Kaneko, S; Nagayasu, K; Nakagawa, T; Nishitani, N; Shirakawa, H; Yamashiro, M | 1 |
| Björkholm, C; Jardemark, K; Schilström, B; Svensson, TH | 1 |
| Nischal, A; Saha, R; Singh, SM | 1 |
| Akar, F; Çelikyurt, İK; Mutlu, O; Türker-Kaya, S; Ulak, G | 1 |
| Figueiredo, T; Mattos, P; Segenreich, D | 1 |
| Lin, CM; Little, K; Reynolds, PM | 1 |
| Mansoor, S; Zubair, UB | 1 |
| Hermida Pérez, B; Izquierdo Romero, M; Rodríguez Prida, J; Salman Monte, Z | 1 |
| Chávez-Castillo, CE; González-Salinas, CG; Medellín-Garibay, SE; Milán-Segovia, RDC; Romano-Moreno, S; Sagahón-Azúa, J | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
| Jauhar, S; Kaufman, KR; Kerr-Gaffney, J; Kurana, S; Strawbridge, R; Yalin, N; Young, AH | 1 |
| Chen, F; Ding, X; Jin, X; Sun, J; Wu, D; Xie, L; Xu, G; Yu, Z | 1 |
| Alexinschi, O; Carvalho, AF; Cavaliere, L; Correll, CU; Cortese, S; Croatto, G; Fiedorowicz, JG; Firth, J; Fusar-Poli, P; Gaina, MA; Makkai, V; Miola, A; Olivola, M; Shin, JI; Soares, FC; Solmi, M; Stubbs, B; Vancampfort, D; Vianello, G; Vieta, E | 1 |
| Burton, DJ; Davey, CG; Garcia-Rodriguez, L; Leonards, CA | 1 |
| Leucht, S; Mavridis, D; Siafis, S; Vieta, E; Yildiz, A | 1 |
26 review(s) available for fluoxetine and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New approaches to managing psychotic depression.
Topics: Affective Disorders, Psychotic; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Electroconvulsive Therapy; Fluoxetine; Humans; Lithium; Mifepristone; Olanzapine; Pirenzepine; Receptors, Glucocorticoid; Treatment Outcome | 2003 |
The combination of olanzapine and fluoxetine in mood disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Combination; Fluoxetine; Half-Life; Humans; Mood Disorders; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Treatment options for bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Lamotrigine; Olanzapine; Patient Education as Topic; Psychotherapy; Psychotherapy, Group; Secondary Prevention; Survival Analysis; Triazines | 2005 |
Clinical highlights in bipolar depression: focus on atypical antipsychotics.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Olanzapine/fluoxetine combination for bipolar depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Expert Testimony; Fluoxetine; Humans; Olanzapine | 2006 |
Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Fluoxetine; Humans; Mood Disorders; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2006 |
[Olanzapine: a second generation antipsychotic drug and an "atypical" mood stabilizer?].
Topics: Affect; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Lithium Compounds; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.
Topics: Benzodiazepines; Depression; Drug Combinations; Fluoxetine; Humans; Olanzapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2008 |
An analysis of the efficacy of treatments for bipolar depression.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Affect; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Differential; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxetine; Humans; Lithium Carbonate; Long-Term Care; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.
Topics: Benzodiazepines; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors; Time Factors | 2010 |
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Prognosis; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2010 |
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Humans; Kidney Diseases; Liver Diseases; Olanzapine; Randomized Controlled Trials as Topic | 2010 |
Treatment options for bipolar depression: a systematic review of randomized, controlled trials.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Lamotrigine; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Treatment Outcome; Triazines | 2010 |
Clinical practice. Bipolar disorder--a focus on depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Dibenzothiazepines; Drug Combinations; Female; Fluoxetine; Humans; Lamotrigine; Olanzapine; Practice Guidelines as Topic; Psychotherapy; Quetiapine Fumarate; Triazines | 2011 |
Evaluation of in vitro percutaneous absorption of olanzapine and fluoxetine HCl: enhancement properties of olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Cellulose; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Membranes, Artificial; Olanzapine; Selective Serotonin Reuptake Inhibitors; Skin; Skin Absorption | 2012 |
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression.
Topics: Animals; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Randomized Controlled Trials as Topic | 2013 |
Acute and maintenance treatments for bipolar depression.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Isoindoles; Lurasidone Hydrochloride; Olanzapine; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2014 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Isoindoles; Lamotrigine; Lithium Compounds; Lurasidone Hydrochloride; Monoamine Oxidase Inhibitors; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles; Treatment Outcome; Triazines; Valproic Acid | 2014 |
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Topics: Aripiprazole; Bipolar Disorder; Citalopram; Fluoxetine; Humans; Lamotrigine; Olanzapine; Quetiapine Fumarate; Venlafaxine Hydrochloride | 2022 |
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Fluoxetine; Glycated Hemoglobin; Humans; Longevity; Olanzapine; Outcome Assessment, Health Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2023 |
Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Fluoxetine; Humans; Lurasidone Hydrochloride; Olanzapine; Young Adult | 2023 |
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Humans; Lamotrigine; Lurasidone Hydrochloride; Male; Middle Aged; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate | 2023 |
32 trial(s) available for fluoxetine and olanzapine
| Article | Year |
|---|---|
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain; Xerostomia | 2000 |
A novel augmentation strategy for treating resistant major depression.
Topics: Ambulatory Care; Basal Ganglia Diseases; Benzodiazepines; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lithium; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Treatment Outcome; Weight Gain | 2001 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Male; Obesity; Olanzapine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain | 2002 |
Influence of fluoxetine on olanzapine pharmacokinetics.
Topics: Adult; Antipsychotic Agents; Asthenia; Benzodiazepines; Cross-Over Studies; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Xerostomia | 2002 |
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
Topics: Antipsychotic Agents; Benzodiazepines; Combat Disorders; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Paroxetine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Wake Disorders; Treatment Outcome | 2002 |
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders | 2002 |
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.
Topics: Adolescent; Adult; Analysis of Variance; Benzodiazepines; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Outpatients; Pirenzepine; Prospective Studies; Schizophrenia; Weight Gain | 2003 |
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Treatment Outcome | 2003 |
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
Topics: Adult; Benzodiazepines; Depressive Disorder; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2003 |
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxetine; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors | 2004 |
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Psychotic Disorders | 2004 |
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Borderline Personality Disorder; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Fluoxetine; Humans; Impulsive Behavior; Olanzapine; Psychiatric Status Rating Scales; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lithium; Longitudinal Studies; Male; Meta-Analysis as Topic; Olanzapine; Proportional Hazards Models; Psychiatric Status Rating Scales; Survival Analysis; Treatment Outcome | 2004 |
Olanzapine augmentation of fluoxetine in body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome | 2005 |
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Placebos; Psychiatric Status Rating Scales; Risk Factors; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Placebos; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Double-Blind Method; Drug Resistance; Drug Synergism; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibitors | 2006 |
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Nortriptyline; Olanzapine; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder, Major; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Obesity; Olanzapine; Regression Analysis; Risk Factors; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Weight Gain | 2005 |
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.
Topics: Benzodiazepines; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2006 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mass Screening; Middle Aged; Olanzapine; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Refusal; Venlafaxine Hydrochloride | 2006 |
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Incidence; Male; Olanzapine; Placebos; Psychiatric Status Rating Scales; Retrospective Studies; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2006 |
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lamotrigine; Male; Olanzapine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Severity of Illness Index; Treatment Outcome; Triazines | 2006 |
[Effects of antidepressant therapy in patients with suspected "angina pectoris" and negative coronary angiogram complicating comorbid depression].
Topics: Aged; Angina Pectoris; Antidepressive Agents, Second-Generation; Benzodiazepines; Coronary Angiography; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine | 2006 |
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Selective Serotonin Reuptake Inhibitors; Treatment Failure | 2007 |
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
Topics: Adolescent; Adult; Benzodiazepines; Bipolar Disorder; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lamotrigine; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome; Triazines; Young Adult | 2009 |
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients.
Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Predictive Value of Tests; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2009 |
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Dopamine beta-Hydroxylase; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Fluoxetine; Genetic Association Studies; Genotype; Humans; Lamotrigine; Male; Olanzapine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Melanocortin, Type 2; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Glucocorticoid; Receptors, Histamine H1; Treatment Outcome; Triazines | 2010 |
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Lamotrigine; Olanzapine; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome; Triazines | 2011 |
Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.
Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Combinations; Fluoxetine; Genetic Association Studies; Genotype; Humans; Linkage Disequilibrium; Norepinephrine Plasma Membrane Transport Proteins; Olanzapine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Melanocortin, Type 3; Selective Serotonin Reuptake Inhibitors; Tryptophan Hydroxylase | 2012 |
95 other study(ies) available for fluoxetine and olanzapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Olanzapine augmentation of fluoxetine in the treatment of trichotillomania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Olanzapine; Pirenzepine; Selective Serotonin Reuptake Inhibitors; Trichotillomania | 1998 |
Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine; Retreatment; Selective Serotonin Reuptake Inhibitors; Treatment Failure | 1998 |
Olanzapine-induced obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine; Schizophrenia | 1999 |
A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Dopamine; Fluoxetine; Frontal Lobe; Haloperidol; Male; Microdialysis; Olanzapine; Pirenzepine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin | 2000 |
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dopamine; Drug Synergism; Extracellular Space; Fluoxetine; Male; Microdialysis; Norepinephrine; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Stimulation, Chemical | 2000 |
Melancholic symptoms during concurrent olanzapine and fluoxetine.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Olanzapine; Pirenzepine | 2000 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine | 2000 |
Antibodies against human putamen in adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Antibodies; Benzodiazepines; Body Mass Index; Caudate Nucleus; Enzyme-Linked Immunosorbent Assay; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine; Putamen; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires | 2001 |
Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report.
Topics: Adolescent; Benzodiazepines; Drug Therapy, Combination; Fluoxetine; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Olanzapine; Pirenzepine; Psychoses, Substance-Induced; Selective Serotonin Reuptake Inhibitors | 2001 |
Olanzapine augmentation for trichotillomania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Olanzapine; Pirenzepine; Trichotillomania | 2001 |
Fluoxetine and olanzapine for resistant depression.
Topics: Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Humans; Metabolic Clearance Rate; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.
Topics: Adult; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanzapine; Pirenzepine; Schizophrenia | 2003 |
Improving identification of treatment effectiveness in bipolar disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Fluoxetine; Humans; Olanzapine; Pirenzepine | 2003 |
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Male; Olanzapine; Pirenzepine | 2003 |
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.
Topics: Action Potentials; Animals; Benzodiazepines; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Fluoxetine; Male; Neural Pathways; Neurons; Olanzapine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2003 |
Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Blood Glucose; Blotting, Western; Body Weight; Corticosterone; Cyclic AMP Response Element-Binding Protein; Drug Interactions; Fluoxetine; Gene Expression; Genes, Immediate-Early; Hippocampus; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Movement; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Long-Evans; Time Factors | 2003 |
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mental Health Services; Middle Aged; Olanzapine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; United States | 2003 |
Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat.
Topics: Animals; Benzodiazepines; Biogenic Monoamines; Brain; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Extracellular Fluid; Fluoxetine; Hypothalamus; Male; Microdialysis; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 2004 |
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Carbazoles; Chlorprothixene; Clopenthixol; Data Collection; Dopamine Antagonists; Female; Fluoxetine; Flupenthixol; Hospitals, Psychiatric; Humans; Male; Mental Disorders; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase Inhibitors; Moscow; Nootropic Agents; Olanzapine; Pharmacoepidemiology; Phenothiazines; Psychotropic Drugs; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride | 2003 |
Olanzapine/Fluoxetine (Symbyax) for bipolar depression.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2004 |
New drug available for bipolar disorder.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Approval; Drug Combinations; Fluoxetine; Humans; Olanzapine; United States | 2004 |
Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain.
Topics: Analysis of Variance; Animals; Benzodiazepines; Blotting, Western; Brain; Cyclic AMP Response Element-Binding Protein; Drug Administration Schedule; Drug Combinations; Drug Synergism; Electrophoretic Mobility Shift Assay; Fibroblast Growth Factor 2; Fluoxetine; Gene Expression Regulation; Male; Olanzapine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Time Factors | 2004 |
Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity.
Topics: Action Potentials; Analysis of Variance; Animals; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Synergism; Fluoxetine; Locus Coeruleus; Male; Neurons; Olanzapine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Time Factors | 2004 |
Serotonin syndrome associated with fluoxetine and olanzapine.
Topics: Benzodiazepines; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2004 |
Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus.
Topics: Actins; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Drug Interactions; Fluoxetine; Injections, Intraperitoneal; Locus Coeruleus; Olanzapine; Rats; Selective Serotonin Reuptake Inhibitors; Tyrosine 3-Monooxygenase; Up-Regulation | 2004 |
Making sense of serotonin toxicity reports, a comment on Chopra et Al. (World J Biol Psychiatry 2004, 5: 114-115).
Topics: Benzodiazepines; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2004 |
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Bromodeoxyuridine; Cell Count; Cell Proliferation; Drug Administration Schedule; Drug Interactions; Endothelial Growth Factors; Fluoxetine; Hippocampus; Immunohistochemistry; Male; Nerve Growth Factors; Nuclear Proteins; O Antigens; Olanzapine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; S100 Calcium Binding Protein beta Subunit; S100 Proteins | 2004 |
Weight loss dynamics during combined fluoxetine and olanzapine treatment.
Topics: Animals; Benzodiazepines; Fluoxetine; Male; Olanzapine; Rats; Rats, Long-Evans; Selective Serotonin Reuptake Inhibitors; Weight Gain; Weight Loss | 2004 |
Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking.
Topics: Benzodiazepines; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Olanzapine; Selective Serotonin Reuptake Inhibitors; Skin; Stereotyped Behavior | 2004 |
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.
Topics: Action Potentials; Animals; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brain; Drug Synergism; Fluoxetine; Infusion Pumps; Injections, Intraperitoneal; Injections, Subcutaneous; Locus Coeruleus; Male; Neurons; Olanzapine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2005 |
Use of olanzapine in anorexia nervosa.
Topics: Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Humans; Olanzapine; Personality Inventory; Research Design; Sample Size; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain | 2005 |
Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Biogenic Monoamines; Dopamine; Extracellular Space; Fluoxetine; Male; Microdialysis; Norepinephrine; Olanzapine; Prefrontal Cortex; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin | 2005 |
Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cocaine-Related Disorders; Data Interpretation, Statistical; Dopamine; Dose-Response Relationship, Drug; Female; Fluoxetine; Haloperidol; Macaca mulatta; Male; Microdialysis; Olanzapine; Selective Serotonin Reuptake Inhibitors; Self Administration | 2006 |
Olanzapine and olanzapine-fluoxetine combination treatment and bipolar I depression.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Codes of Ethics; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Peer Review, Research; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Anisotropic lattice contraction in pharmaceuticals: the influence of cryo-crystallography on calculated powder diffraction patterns.
Topics: Anisotropy; Benzodiazepines; Chemistry, Pharmaceutical; Crystallography, X-Ray; Databases, Factual; Fluoxetine; Models, Molecular; Olanzapine; Pharmaceutical Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors; Temperature | 2006 |
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.
Topics: Accidents; Acute Disease; Adult; Akathisia, Drug-Induced; Benzodiazepines; Drug Overdose; Dystonia; Emergency Service, Hospital; Fluoxetine; Humans; Male; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2006 |
[A 74-year-old unconscious woman with myoclonia and seizures].
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Citalopram; Female; Fluoxetine; Humans; Mianserin; Myoclonus; Olanzapine; Poisoning; Seizures; Selective Serotonin Reuptake Inhibitors; Unconsciousness | 2006 |
Successful treatment of anorexia with a combination of high-dose olanzapine, fluoxetine and mirtazapine.
Topics: Adult; Anorexia; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Mirtazapine; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2006 |
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Corticosterone; Desoxycorticosterone; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Gas Chromatography-Mass Spectrometry; Hippocampus; Male; Olanzapine; Pregnanolone; Pregnenolone; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2006 |
Does olanzapine have any antidepressant effect?
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Utilization Review; Female; Fluoxetine; Humans; Hyperprolactinemia; Italy; Male; Medical Records; Mental Disorders; Olanzapine; Paroxetine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Sertraline; Treatment Outcome | 2008 |
The empirical redefinition of the psychometric criteria for remission in bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Follow-Up Studies; Humans; Lamotrigine; Olanzapine; Personality Assessment; Psychiatric Status Rating Scales; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome; Triazines | 2008 |
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Randomized Controlled Trials as Topic; Regression Analysis; Survival Analysis; Treatment Outcome | 2007 |
Water, water, everywhere, nor any drop to drink: climate change delusion.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Climate; Clonazepam; Dehydration; Delusions; Depressive Disorder; Fluoxetine; GABA Modulators; Greenhouse Effect; Humans; Male; Olanzapine; Psychotic Disorders; Water Supply | 2008 |
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Olanzapine; Personality Inventory; Psychometrics; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Olanzapine plus 17-beta estradiol produce antidepressant-like actions in rats forced to swim.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Female; Fluoxetine; Male; Motor Activity; Olanzapine; Ovariectomy; Pregnanolone; Progesterone; Rats; Selective Serotonin Reuptake Inhibitors; Swimming | 2009 |
Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Topics: Affect; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Dibenzothiazepines; Double-Blind Method; Fluoxetine; Health Status; Humans; Markov Chains; Olanzapine; Quality-Adjusted Life Years; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Valproic Acid | 2009 |
Treatment-resistant bipolar depression: towards a new definition.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Resistance; Evidence-Based Practice; Fluoxetine; Humans; Lithium; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic | 2009 |
Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Creatine Kinase, BB Form; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Male; Olanzapine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2009 |
Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms.
Topics: Benzodiazepines; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Fluoxetine; Hydrolysis; Olanzapine; Oxidation-Reduction; Tablets | 2009 |
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Placebos; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2009 |
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.
Topics: Antipsychotic Agents; Benzodiazepines; Ectoparasitic Infestations; Female; Fluoxetine; Haloperidol; Humans; Imipramine; Male; Middle Aged; Olanzapine; Pimozide; Retrospective Studies; Risperidone; Schizophrenia, Paranoid; Sertraline | 2010 |
Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain.
Topics: Animals; Benzodiazepines; Brain; Citrate (si)-Synthase; Fluoxetine; Male; Olanzapine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2011 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluoxetine; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Meta-Analysis as Topic; Middle Aged; Olanzapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Prolactin; Protein Serine-Threonine Kinases; Psychotic Disorders; Receptors, Dopamine D2; Sex Characteristics | 2011 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.
Topics: Anorexia Nervosa; Benzodiazepines; Child; Diseases in Twins; Family Therapy; Female; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Twins, Monozygotic; Weight Gain | 2012 |
Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Male; Neurotrophin 3; Olanzapine; Prefrontal Cortex; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Up-Regulation | 2011 |
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
Topics: Amlodipine; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Clonazepam; Drug Therapy, Combination; Fluoxetine; GABA Modulators; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Raynaud Disease; Schizophrenia; Vasodilator Agents | 2011 |
Development of a rapid and sensitive SPE-LC-MS/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma.
Topics: Benzodiazepines; Chromatography, High Pressure Liquid; Drug Stability; Fluoxetine; Humans; Linear Models; Olanzapine; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2012 |
Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Male; Maze Learning; Olanzapine; Rats; Rats, Wistar; Risperidone; Treatment Outcome | 2011 |
Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.
Topics: Animals; Anorexia; Benzodiazepines; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Female; Fluoxetine; Mice; Motor Activity; Olanzapine; Running; Selective Serotonin Reuptake Inhibitors; Survival Rate | 2012 |
Electroconvulsive therapy in the presence of atrial septal defect: a case report.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Delusions; Depressive Disorder; Electrocardiography; Electroconvulsive Therapy; Fluoxetine; Heart Septal Defects, Atrial; Humans; Male; Olanzapine; Young Adult | 2012 |
Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Benzodiazepines; Depression; Disease Models, Animal; Fluoxetine; Injections, Intraperitoneal; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Olanzapine; Stress, Psychological; Thiazepines | 2012 |
Repeated activation of mania by atypical antipsychotics in a patient.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Humans; Loxapine; Medication Adherence; Middle Aged; Olanzapine; Recurrence; Risperidone; Schizophrenia | 2012 |
[The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Olanzapine; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulpiride; Treatment Outcome; Young Adult | 2012 |
The effects of tianeptine, olanzapine and fluoxetine on the cognitive behaviors of unpredictable chronic mild stress-exposed mice.
Topics: Animals; Benzodiazepines; Brain-Derived Neurotrophic Factor; Cognition; Cyclic AMP Response Element-Binding Protein; Fluoxetine; Male; Maze Learning; Memory; Mice; Mice, Inbred BALB C; Olanzapine; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Thiazepines | 2013 |
Convolution of emission derivative ratio curves of closely related fluorescent reaction products using discrete fourier functions and non-parametric linear regression method.
Topics: 4-Chloro-7-nitrobenzofurazan; Benzodiazepines; Coloring Agents; Fluoxetine; Linear Models; Olanzapine; Regression Analysis; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared | 2014 |
[Buccolingual dyskinesia with justified hallucinations].
Topics: Alcoholism; Benzodiazepines; Clonazepam; Depressive Disorder; Dibenzothiazepines; Disulfiram; Female; Fluoxetine; Foreign Bodies; Hallucinations; Humans; Middle Aged; Movement Disorders; Olanzapine; Pharynx; Quetiapine Fumarate; Tetrabenazine; Tongue Habits | 2014 |
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.
Topics: Animals; Antidepressive Agents; Benzodiazepines; Bicuculline; Citalopram; Depressive Disorder; Disease Models, Animal; Dorsal Raphe Nucleus; Female; Fluoxetine; GABA-A Receptor Antagonists; GABAergic Neurons; Male; Mice, Inbred C57BL; Neural Inhibition; Olanzapine; Piperazines; Rats, Wistar; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin Antagonists; Sulfonamides; Tissue Culture Techniques | 2015 |
Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluoxetine; Ketamine; Male; Olanzapine; Prefrontal Cortex; Pyramidal Cells; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Synaptic Transmission; Tissue Culture Techniques | 2015 |
Obsessive slowness presenting as catatonia in a patient with Borderline Intelligence.
Topics: Behavioral Symptoms; Benzodiazepines; Catatonia; Diagnosis, Differential; Fluoxetine; Humans; Intellectual Disability; Intelligence Tests; Male; Obsessive Behavior; Olanzapine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2015 |
Tianeptine, olanzapine and fluoxetine show similar restoring effects on stress induced molecular changes in mice brain: An FT-IR study.
Topics: Animals; Antidepressive Agents; Benzodiazepines; Brain; Brain Chemistry; Fluoxetine; Lipid Peroxidation; Male; Membrane Fluidity; Mice; Mice, Inbred BALB C; Olanzapine; Stress, Psychological; Thiazepines | 2016 |
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2016 |
Delayed Serotonin Syndrome in the Setting of a Mixed Fluoxetine and Serotonin Antagonist Overdose.
Topics: Benzodiazepines; Bupropion; Cyproheptadine; Dopamine Uptake Inhibitors; Drug Overdose; Fluoxetine; Humans; Male; Olanzapine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists; Serotonin Syndrome; Time Factors; Trazodone; Young Adult | 2018 |
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.
Topics: Bipolar Disorder; Delusions; Depression; Depressive Disorder; Emotions; Female; Fluoxetine; Humans; Love; Olanzapine; Psychotic Disorders; Young Adult | 2019 |
Cameron lesions and selective serotonin reuptake inhibitors: An uncommon combination.
Topics: Aged; Anxiety Disorders; Female; Fluoxetine; Gastrointestinal Hemorrhage; Gastroscopy; Hernia, Hiatal; Humans; Melena; Olanzapine; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors; Stomach Ulcer | 2020 |
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Topics: Adult; Antipsychotic Agents; Anxiety; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluoxetine; Genotype; Humans; Male; Medication Adherence; Mental Disorders; Mexico; Middle Aged; Olanzapine; Pharmacogenomic Variants; Pharmacokinetics; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2021 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |
Olanzapine add-on treatment promotes neuronal differentiation of neural stem cells compared with fluoxetine alone.
Topics: Antidepressive Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Fluoxetine; Humans; Infant, Newborn; Neural Stem Cells; Neurogenesis; Olanzapine | 2022 |